3Denton M,Todd NJ,Kerr KG,et al. Molecular ep idem iology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and assoliated environ-mental sam pies[J]. Jclin Microbiol,1998,36(7):1953-1958.
二级参考文献8
11，National Committee for Clinical Laboratory Standards.Performance standards for antimicrobial disk suceptibility testings[M].NCCLS,1999,19(1):58.
22，Jarlier V,Nicolas MH,Fournier G et al.Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae:hospital prevalence and susceptibility patterns[J].Rev Infect Dis,1988,10:867-878.
33，Philippon A,Arlet G,Lagrange PH.Origin and impact of plasmid-mediated extended-spectrum β-lactamases[J].Eur J Clin Microbiol Infect Dis,1994,13:17-29.
44，Phlleron NJ,Bradbury JF.Stenotrophomonas,a new bacterial genus for Xanthomonas maltophilia[J].Int J Syst Bateriol,1993,43:606-609.
55，Bush K,Jacoby GA,Medeiros AA.A functional classification scheme for β-lactam and its correlation with molecular structure[J].Antimicrob Agents Chemother,1995,39:1211-1233.
66，National Committee for Clinical Laboratory Standards.MIC interpretive standards for Pseudomonas aeruginosa and other non-Enterabacteriaceae approved standard[J].NCCLS,1999,19(1):76-77.
77，Poulos CD,Matsumura SO,Willey BM et al.In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilis[J].Antimiciob Agents Chemother,1995,39(10):2220-2223.
88，Garcia Sanchez JE,Vazquez Lopez ML,Blazquez de Castro AM et al.Aztreonam/clavulanic acid in the treatment of serious infections caused by Stenotrophomonas maltophilia in neutropenic patients:case reports[J].J Chemother,1997,9(3):238-240.
